During a live event, Binod Dhakal, MD, discussed the evidence for targeting XPO1 and GPRC5D before BCMA CAR T-cell therapy in multiple myeloma.

Phase 1 clinical data in patients with Parkinson’s disease demonstrating reduction in endolysosomal and neuroinflammatory ...

CAR-modified stem cell memory T cells show greater expansion and persistence than standard CAR T cells, enabling complete ...

Kyverna Therapeutics, Inc. (Nasdaq: KYTX), a late-stage clinical biopharmaceutical company focused on developing cell therapies for patients with autoimmune diseases, today announced the appointment ...

A bone marrow transplant can buy time for people with aggressive B-cell cancers. Too often, it does not buy enough. For ...

CAR T-cell therapy has transformed the treatment of hematologic malignancies, yet many patients do not achieve lasting ...

TP53 alterations independently predicted inferior remission, EFS, and OS after CAR T-cell therapy in relapsed/refractory B-ALL.

Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and ...

CAR T-cell therapy has transformed the treatment of hematologic malignancies, yet many patients do not achieve lasting benefit – often because the ...

Oncology pharmacists can operationalize payer-mediated transitions such as biosimilar adoption, minimizing clinician burden while reducing waste and total cost of care. Earlier CAR T-cell therapy ...

Stem-cell memory T (TSCM) cells are a rare subset of immune cells with the ability to self-renew, persist long term, and ...

Laguna Biotherapeutics, Inc. (Laguna), a clinical-stage biotechnology company focused on novel live bacterial therapeutics, today announced that the U.S. Food and Drug Administration (FDA) has cleared ...